<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(45)</volume><submitter>Kazakova E</submitter><pubmed_abstract>Yellow fever virus (YFV) transmitted by infected mosquitoes causes an acute viral disease for which there are no approved small-molecule therapeutics. Our recently developed machine learning models for YFV inhibitors led to the selection of a new pyrazolesulfonamide derivative &lt;b>RCB16003&lt;/b> with acceptable &lt;i>in vitro&lt;/i> activity. We report that the &lt;i>N&lt;/i>-phenyl-1-(phenylsulfonyl)-1&lt;i>H&lt;/i>-1,2,4-triazol-3-amine class, which was recently identified as active non-nucleoside reverse transcriptase inhibitors against HIV-1, can also be repositioned as inhibitors of yellow fever virus replication. As compared to other &lt;i>Flaviviridae&lt;/i> or &lt;i>Togaviridae&lt;/i> family viruses tested, both compounds &lt;b>RCB16003&lt;/b> and &lt;b>RCB16007&lt;/b> demonstrate selectivity for YFV over related viruses, wit</pubmed_abstract><journal>ACS omega</journal><pagination>42951-42965</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10653066</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>1-Sulfonyl-3-amino-1&lt;i>H&lt;/i>-1,2,4-triazoles as Yellow Fever Virus Inhibitors: Synthesis and Structure-Activity Relationship.</pubmed_title><pmcid>PMC10653066</pmcid><pubmed_authors>Riabova O</pubmed_authors><pubmed_authors>Ekins S</pubmed_authors><pubmed_authors>Kazakova E</pubmed_authors><pubmed_authors>Makarov V</pubmed_authors><pubmed_authors>Puhl AC</pubmed_authors><pubmed_authors>Lane TR</pubmed_authors><pubmed_authors>Jones T</pubmed_authors></additional><is_claimable>false</is_claimable><name>1-Sulfonyl-3-amino-1&lt;i>H&lt;/i>-1,2,4-triazoles as Yellow Fever Virus Inhibitors: Synthesis and Structure-Activity Relationship.</name><description>Yellow fever virus (YFV) transmitted by infected mosquitoes causes an acute viral disease for which there are no approved small-molecule therapeutics. Our recently developed machine learning models for YFV inhibitors led to the selection of a new pyrazolesulfonamide derivative &lt;b>RCB16003&lt;/b> with acceptable &lt;i>in vitro&lt;/i> activity. We report that the &lt;i>N&lt;/i>-phenyl-1-(phenylsulfonyl)-1&lt;i>H&lt;/i>-1,2,4-triazol-3-amine class, which was recently identified as active non-nucleoside reverse transcriptase inhibitors against HIV-1, can also be repositioned as inhibitors of yellow fever virus replication. As compared to other &lt;i>Flaviviridae&lt;/i> or &lt;i>Togaviridae&lt;/i> family viruses tested, both compounds &lt;b>RCB16003&lt;/b> and &lt;b>RCB16007&lt;/b> demonstrate selectivity for YFV over related viruses, wit</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Nov</publication><modification>2025-04-04T09:30:22.778Z</modification><creation>2025-04-04T09:30:22.778Z</creation></dates><accession>S-EPMC10653066</accession><cross_references><pubmed>38024733</pubmed><doi>10.1021/acsomega.3c06106</doi></cross_references></HashMap>